Related Experiment Videos
Exploring the mechanisms of action of FB642 at the cellular level
L A Hammond1, K Davidson, R Lawrence
1Institute for Drug Development, Cancer Therapy & Research Center, 8122 Datapoint Drive 650, San Antonio, TX 78229, USA. lhammond@saci.org
Abstract:
FB642(methyl-2-benzimidazolecarbamate, carbendazim) is a systemic fungicide belonging to the benzimidazole family with antitumor activity against a broad spectrum of tumors both in vitro and in vivo such as pancreas, prostate, colon, and breast. Although the preclinical antitumor activity of FB642 has been well explored, its mechanism of action has not been as well delineated. Previous studies indicate that FB642 may interfere with mitosis and thus may disrupt or inhibit microtubule function resulting in apoptosis. This study seeks to determine if FB642 is a sufficiently novel agent worthy of further development by examining the effect of FB642 on apoptosis, the cell cycle, p53-positive and -negative tumors, and drug-resistant and MDR cell lines. The results of this present study indicate that FB642 increases the degree of apoptosis in all examined tumor cell lines, may induce G2/M uncoupling, may selectively kill p53 abnormal cells, and exhibits antitumor activity in drug- and multidrug-resistant cell lines. The induction of apoptosis by FB642, particularly in p53-deficient cells, its impressive in vivo activity against a broad spectrum of murine and human tumors, as well as an acceptable toxicity profile in animals, make FB642 an excellent candidate for further evaluation in clinical trials in cancer patients.
Insights
Carbendazim (FB642), a benzimidazole fungicide, shows significant antitumor potential by inducing apoptosis and selectively targeting p53-deficient cells. Its activity against resistant cell lines suggests promise for cancer clinical trials.
Area of Science:
- Pharmacology and Toxicology
- Cancer Biology and Therapeutics
Background:
- Carbendazim (FB642), a benzimidazole fungicide, exhibits preclinical antitumor activity across various cancer types (pancreas, prostate, colon, breast).
- The precise mechanism of action for carbendazim's antitumor effects, potentially involving microtubule disruption and apoptosis, requires further elucidation.
Purpose of the Study:
- To evaluate carbendazim (FB642) as a novel anticancer agent by examining its effects on apoptosis, cell cycle, p53 status, and drug resistance.
- To determine the potential of carbendazim for further clinical development based on its efficacy and toxicity profile.
Main Methods:
- In vitro and in vivo studies assessing the impact of carbendazim (FB642) on tumor cell lines.
- Analysis of apoptosis induction, cell cycle progression (G2/M phase), and effects on p53-positive and -negative tumors.
- Evaluation of carbendazim's efficacy in drug-resistant and multidrug-resistant (MDR) cancer cell lines.
Main Results:
- Carbendazim (FB642) significantly increased apoptosis across all tested tumor cell lines.
- The agent demonstrated potential for inducing G2/M cell cycle uncoupling and selective killing of p53-abnormal cells.
- Carbendazim exhibited notable antitumor activity against drug- and multidrug-resistant cell lines.
Conclusions:
- Carbendazim (FB642) effectively induces apoptosis, particularly in p53-deficient cells, and shows broad-spectrum antitumor activity.
- Its efficacy in resistant cell lines and acceptable animal toxicity profile position carbendazim as a strong candidate for clinical cancer trials.